List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 811 studies with search of: Interferon alfa-2 OR "Roferon-A (2a) OR Intron A (2b)"[TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Active, not recruiting Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma
Conditions: Lymphoma;   Precancerous/Nonmalignant Condition
Interventions: Biological: PEG-interferon alfa-2b;   Biological: Interferon alfa-2b;   Drug: Valproic Acid;   Drug: Zidovudine;   Genetic: Molecular Evaluation/Analysis of Malignant Clones of ATLL;   Genetic: NF-kB Inhibition
2 Active, not recruiting Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Conditions: Stage IA Skin Melanoma;   Stage IB Skin Melanoma;   Stage IIA Skin Melanoma;   Stage IIB Skin Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
3 Terminated
Has Results 		Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Decitabine;   Drug: Interferon Alfa-2b
4 Recruiting Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Dialysis Patients With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Pegylated interferon alfa-2a plus low dose ribavirin;   Drug: Pegylated interferon alfa
5 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
6 Completed
Has Results 		Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
Conditions: Chronic Hepatitis C;   Hemodialysis
Intervention: Drug: Pegylated interferon alfa-2a and ribavirin
7 Recruiting Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1
Condition: Chronic Hepatitis C
Interventions: Drug: IFN alfa-2b XL 27 MUI + Ribavirin;   Drug: IFN alfa-2b XL 36 MUI + Ribavirin;   Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
8 Unknown † Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
Condition: Hepatitis C
Intervention: Drug: Pegylated interferon alfa-2a
9 Terminated PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: PEG-interferon alfa-2b;   Drug: PEG-interferon alfa-2b
10 Completed Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Solid Tumors
Interventions: Drug: Sodium Stibogluconate;   Drug: Interferon Alpha-2b
11 Completed Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: PEG-interferon alfa-2b;   Drug: decitabine
12 Not yet recruiting Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.
Condition: Chronic Hepatitis C
Intervention: Biological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
13 Not yet recruiting Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Aspirin
14 Completed Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Condition: Stage IV Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Drug: cisplatin;   Drug: sodium stibogluconate;   Drug: dacarbazine;   Drug: vinblastine
15 Terminated Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
Condition: Hepatitis C, Chronic
Interventions: Drug: peg-interferon alfa-2b;   Drug: ribavirin;   Drug: amantadine
16 Unknown † Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
Condition: Non-Melanomatous Skin Cancer
Interventions: Biological: PEG-interferon alfa-2a;   Drug: gefitinib
17 Unknown † Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
Conditions: Chronic Hepatitis B;   Chronic Hepatitis D
Intervention: Drug: pegylated IFN alfa-2b plus ribavirin
18 Completed A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
Condition: HIV Infections
Interventions: Drug: Interferon alfa-2a;   Drug: Zidovudine;   Drug: Zalcitabine
19 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b
20 Withdrawn Study to Evaluate Sodium Stibogluconate With Interferon Alpha-2b
Conditions: Advanced Cancer;   Solid Tumors
Interventions: Drug: Sodium Stibogluconate;   Drug: Interferon Alpha-2b

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services